Advances in the field of nanooncology.
Advances in the field of nanooncology.
复制标题
DOI：
10.1186/1741-7015-8-83
复制
发表时间：
2010-12-13
期刊：
影响因子：
9.3
通讯作者：
Jain KK
中科院分区：
文献类型：
--
作者：
Jain KK
纳米肿瘤学，纳米生物技术在癌症管理中的应用，是目前纳米医学中最重要的一章。纳米生物技术已经完善和扩展了癌症分子诊断的极限，例如，通过使用金纳米颗粒和量子点。纳米生物技术还改善了癌症生物标志物的发现，其中一个例子是通过纳米生物传感器对多种蛋白质生物标志物的灵敏检测。磁性纳米颗粒可以捕获血液中的循环肿瘤细胞，然后进行快速光声检测。纳米颗粒能够在癌症中实现靶向药物递送，其通过减少所施用的抗癌药物的剂量来增加功效并减少副作用。纳米抗癌药物可以穿过某些生物屏障，在肿瘤中达到治疗浓度，并使周围正常组织免受毒性作用。纳米粒子结构促进了各种形式的能量的递送，用于外科手术不可及的恶性肿瘤的非侵入性热破坏。肿瘤的基于纳米颗粒的光学成像以及通过磁共振成像增强肿瘤检测的造影剂可以与癌症治疗剂的递送组合。单克隆抗体纳米颗粒复合物正在研究用于诊断以及癌症治疗的靶向递送。基于纳米颗粒的化疗药物已经上市，其中几种正在进行临床试验。癌症治疗的个性化是基于在分子水平上更好地了解疾病，这是由纳米生物技术促进的。纳米生物技术将促进诊断与治疗的结合，这是癌症个性化医学方法的一个重要特征。
Nanooncology, the application of nanobiotechnology to the management of cancer, is currently the most important chapter of nanomedicine. Nanobiotechnology has refined and extended the limits of molecular diagnosis of cancer, for example, through the use of gold nanoparticles and quantum dots. Nanobiotechnology has also improved the discovery of cancer biomarkers, one such example being the sensitive detection of multiple protein biomarkers by nanobiosensors. Magnetic nanoparticles can capture circulating tumor cells in the bloodstream followed by rapid photoacoustic detection. Nanoparticles enable targeted drug delivery in cancer that increases efficacy and decreases adverse effects through reducing the dosage of anticancer drugs administered. Nanoparticulate anticancer drugs can cross some of the biological barriers and achieve therapeutic concentrations in tumor and spare the surrounding normal tissues from toxic effects. Nanoparticle constructs facilitate the delivery of various forms of energy for noninvasive thermal destruction of surgically inaccessible malignant tumors. Nanoparticle-based optical imaging of tumors as well as contrast agents to enhance detection of tumors by magnetic resonance imaging can be combined with delivery of therapeutic agents for cancer. Monoclonal antibody nanoparticle complexes are under investigation for diagnosis as well as targeted delivery of cancer therapy. Nanoparticle-based chemotherapeutic agents are already on the market, and several are in clinical trials. Personalization of cancer therapies is based on a better understanding of the disease at the molecular level, which is facilitated by nanobiotechnology. Nanobiotechnology will facilitate the combination of diagnostics with therapeutics, which is an important feature of a personalized medicine approach to cancer.
登录
查看更多内容
DOI：
10.2217/nnm.10.49
发表时间：
2010-07
期刊：
Nanomedicine (London, England)
影响因子：
--
作者：
Kosaka N;McCann TE;Mitsunaga M;Choyke PL;Kobayashi H
通讯作者：
Kobayashi H
影响因子：
11.2
作者：
Kumar M;Yigit M;Dai G;Moore A;Medarova Z
通讯作者：
Medarova Z
影响因子：
50.5
作者：
Matsumura, Y;Gotoh, M;Takahashi, K
通讯作者：
Takahashi, K
影响因子：
2.8
作者：
Jain, KK
通讯作者：
Jain, KK
影响因子：
4.9
作者：
Cinteza, Ludmila O.;Ohulchanskyy, Tymish Y.;Prasad, Paras N.
通讯作者：
Prasad, Paras N.